The patient is hypoxemic, the HRCT is on the screen, and you have ninety seconds before rounds reach the bedside to decide whether this is fibrotic hypersensitivity pneumonitis or IPF — and the management implications are opposite. Apply the wrong framework and immunosuppression harms the patient, antifibrotic therapy is delayed, or a treatable antigen exposure is missed for another six months. This handbook delivers the structured clinical decision frameworks that transform pattern recognition from intuition into a reproducible discipline at the point of care. Inside this book: • Pulmonary Signature Decoder System — 51 indexed signatures across HRCT, PFTs, clinical phenotype, ventilator mechanics, and ABG decision domains, scannable on call or before rounds • Three-density sign decoded — distinguish fibrotic HP from IPF before initiating therapy that could harm the wrong patient • Molecular profiling framework for advanced NSCLC — EGFR, ALK, ROS1, BRAF, KRAS G12C, MET, RET, NTRK, and PD-L1 mapped to first-line therapy selection • Mucormycosis recognition in DKA and neutropenia — empiric therapy and surgical timing when biopsy confirmation will arrive too late • EOLIA-based ECMO referral logic — proactive criteria before deterioration forecloses the option • BPaL and BPaLM regimens for MDR-TB — six-month oral therapy replacing the eighteen-month injectable era • Sotatercept in PAH — activin signaling inhibition integrated into risk-stratified combination therapy • Master Atlas Section 28 — every signature consolidated for clinic, call, and rotation reference Written for Pulmonary and Critical Care fellows, internal medicine residents on pulmonary rotation, hospitalists, and advanced practice providers managing respiratory disease. Open this handbook and commit to the structured framework your next critically ill pulmonary patient deserves.
